How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Outbreaks News Archives

Login / Signup

Early Release – High Genetic Diversity of Histoplasma in the Amazon Basin, 2006–2017 – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Communicable disease threats report, 10-16 May 2025, week 20

Early Release – Prevalence of Nitroimidazole-Refractory Giardiasis Acquired in Different World Regions, Sweden, 2008–2020 – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Early Release – Art of the Interwoven – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Early Release – OXA-204 Carbapenemase in Clinical Isolate of Pseudomonas guariconensis, Tunisia – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Early Release – Mycoplasma arginini Cellulitis, Tenosynovitis, and Arthritis in Kidney Transplant Recipient, Slovenia, 2024 – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Early Release – Systematic Review of Contact Investigation Costs for Tuberculosis, United States – Volume 31, Number 7—July 2025 – Emerging Infectious Diseases journal

Early Release – Cadaveric Human Growth Hormone–Associated Creutzfeldt-Jakob Disease with Long Latency Period, United States – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Early Release – Investigation of Influenza A(H5N1) Virus Neutralization by Quadrivalent Seasonal Vaccines, United Kingdom, 2021–2024 – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Early Release – Francisella tularensis Subspecies holarctica in Stranded Beluga Whales, Cook Inlet, Alaska, USA – Volume 31, Number 6—June 2025 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us